EPYSQLI® (Eculizumab-aagh) — A Landmark Biosimilar in Rare Disease Treatment
Introduction Samsung Bioepis’ EPYSQLI® (eculizumab-aagh) has earned FDA approval as a biosimilar to Soliris® (eculizumab). Approved on July 19, 2024, EPYSQLI offers a more affordable alternative for treating debilitating rare diseases.FDA Access DataSamsung BioepisU.S. Pharmacist Indications EPYSQLI is indicated for: Efficacy & Clinical Performance EPYSQLI matches the reference biologic in both efficacy and safety: Cost […]
Byetta (Exenatide): A Leap Forward in Type 2 Diabetes Management
Key Details from the FDA Record (NDA 021773) Indication & Efficacy Mechanism of Action Byetta is a GLP-1 receptor agonist. It: Patent & Exclusivity Insights